Boehringer Ingelheim International Gmbh

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Karl Thomae Gmbh

Other

Boehringer Ingelheim Pharma Kg

Guenter Linz

Frank Himmelsbach

Helmut Pieper

Johannes M Weisenberger

Thomas Mueller

Peter Sieger

Rolf Schmid

Volkhard Austel

Gerd Kraemer

Werner Rall

Wolfgang Eisert

Matthias Hoffmann

Adil Duran

Matthias Grauert

Rainer Soyka

Georg Dahmann

Gerald Juergen Roth

Joerg Kley

Gerhard Schaenzle

Andreas Schnapp

Sandra Handschuh

Edward Walker

Dennis Fiegen

Frank Hilberg

Juergen Schnaubelt

Jasna Klicic

Armin Heckel

Thorsten Lehmann-Lintz

Markus Ostermeier

Stephen East

Ulrike Tontsch-Grunt

Jacobus C A Van Meel

Daniel Bischoff

Elke Seewaldt-Becker

Ludwig Gutschera

Geert Asche

Michael Philip Mazanetz

Rolf Herter

Robert John Scott

Gunnar Schreiner

Gerd Krueger

Svenja Renner

Carsten Reichel

Stefan Goepper

Juergen Daeubler

Joern Merten

Stephen Peter East

Zeno A Leuter

Michael Pangerl

Thomas Bock

Austel: Volkhard

Volhard Austel

Austel Volkhard

Sandra Stehle

Andr&eacute; Steiner

Sarah Unger

Robert Schiffers

Claudia Ochs

Sabrina Kusserow

Daniel Haerle

Stephen P East

Thomas Ebner

Gerd F Kraemer

This invention relates to a novel process for making alkyl 7-amino-5-methyl-[1,2,5]-oxadiazolo[3,4-b]pyridine-carboxylate.

Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein wherein n is either 0 or 1,

Substituted naphthyridines and their use as medicaments

The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.

Selective synthesis of functionalized pyrimidines

The present invention relates to a novel process for the preparation of compounds of general formula (I) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.

Process for the preparation of acylguanidines and acylthioureas

The present invention relates to a method of making pyrimidines of formula (III) said method comprising reacting a compound of formula (I) with an oxygen, sulfur or nitrogen nucleophile of formula T-H; and reacting the compound obtained with an amine of formula (II) [HN(R1)R2] to form a compound of formula (III) wherein X1, X2, T, R1 and R2 have the meanings as defined herein. 

Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives

The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallization in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.

Specific salt, anhydrous and crystalline form of a dihydropteridione derivative

The present invention encompasses a process for preparing compounds of formula (1), wherein a compound of formula (2) is reacted in the presence of a catalyst and a solvent under hydrogen pressure to form a compound of formula (1) and wherein A and R&#x2014;Rare defined herein.

Method of preparing chiral cyclic &#x3b2;-aminocarboxamides

The present invention relates to a method of making pyrimidines of formula (III), wherein X1, X2, R1 and R2 have the meanings as defined herein.

Regioselective preparation of substituted pyrimidines

The present invention relates to a crystalline form a dihydropteridione derivative, namely a crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.

Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide

The present invention relates to a process for the manufacture of a specific indolinone derivative and a pharmaceutically acceptable salt thereof, namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone and its monoethanesulfonate, to new manufacturing steps and to new intermediates of this process.

Process for the manufacture of an indolinone derivative

Disclosed are hydrates and polymorphs of 4- [[(7R)-8-cyclopentyl-7 -ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide: as well as, processes for preparing them and their use as pharmaceutical compositions with antiproliferative activity.

[object Object]

Disclosed are processes and intermediate compounds for preparing dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and in the specification.

Intermediate compounds useful for the manufacture of dihydropteridinones

Disclosed are processes for preparing dihydropteridinones of general formula (I) wherein the groups L and R-Rhave the meanings given in the claims and in the specification.

Process for the manufacture of dihydropteridinones

Growing community of inventors

Mittelbiberach, Germany

Guenter Linz